SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
18.82
-0.46 (-2.39%)
May 9, 2025, 5:29 PM CET
159.23%
Market Cap 922.35M
Revenue (ttm) n/a
Net Income (ttm) -82.40M
Shares Out 49.01M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 193,703
Average Volume 200,427
Open 19.00
Previous Close 19.28
Day's Range 18.52 - 19.16
52-Week Range 6.63 - 23.45
Beta 1.22
RSI 48.77
Earnings Date May 27, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.